Psma Positive Metastatic Castration Resistant Prostate Cancer clinical trials

Explore recruiting psma positive metastatic castration resistant prostate cancer clinical trials.

Recruiting psma positive metastatic castration resistant prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Psma Positive Metastatic Castration Resistant Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer

Spain, Slovakia, Czechia, Sweden, Belgium, France +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, randomized, open-label, multi-center study of JSB462 in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)

Netherlands, Austria, Germany, Italy, France, Czechia +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-label Dosimetry, Biodistribution, Tolerability and Safety Study of lutetium (177Lu) vipivotide tetraxetan in Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Moderately and Severely Impaired and with normal Renal Function

Italy, Germany, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)

Germany, France, Spain, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mHSPC) and in men with heavily pre-treated PSMA positive metastatic castration resistant prostate cancer (mCRPC) with or without prior 177Lu-labelled PSMA-targeted radioligand therapy

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Psma Positive Metastatic Castration Resistant Prostate Cancer trials by city

Psma Positive Metastatic Castration Resistant Prostate Cancer in Toronto Psma Positive Metastatic Castration Resistant Prostate Cancer in Vancouver Psma Positive Metastatic Castration Resistant Prostate Cancer in Montreal Psma Positive Metastatic Castration Resistant Prostate Cancer in Calgary Psma Positive Metastatic Castration Resistant Prostate Cancer in Edmonton Psma Positive Metastatic Castration Resistant Prostate Cancer in Ottawa Psma Positive Metastatic Castration Resistant Prostate Cancer in Winnipeg Psma Positive Metastatic Castration Resistant Prostate Cancer in Quebec City Psma Positive Metastatic Castration Resistant Prostate Cancer in Hamilton Psma Positive Metastatic Castration Resistant Prostate Cancer in Kitchener Psma Positive Metastatic Castration Resistant Prostate Cancer in London Psma Positive Metastatic Castration Resistant Prostate Cancer in Halifax Psma Positive Metastatic Castration Resistant Prostate Cancer in New York Psma Positive Metastatic Castration Resistant Prostate Cancer in Los Angeles Psma Positive Metastatic Castration Resistant Prostate Cancer in Chicago Psma Positive Metastatic Castration Resistant Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease